DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Mamounas EP, Bandos H, Lembersky BC. et al.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol 2019;
20: 88-99
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.